TeselaGen Biotechnology is a software company developing an industry-leading computer aided design (CAD) platform for designing and testing DNA sequences for use in biotech products, such as engineered microorganisms or virus-like particles. The platform generates protocols for molecular cloning methods and DNA library assembly. It is based on the j5 software platform developed by scientists, including co-founder Nathan Hillson, at Joint BioEnergy Institute (JBEI). The company was founded in 2011 and is headquartered in San Francisco, California.
On October 4, 2017 TeselaGen Biotechnology announced reaching a partnership agreement with the protein design software company Arzeda. The partnership allows Arzeda to license TeselaGen Biotechnology's cloud informatics solutions and collaborate with TeselaGen Biotechnology to create a biological design platform. The CEO of TeselaGen Biotechnology, Michael Fero, made the following comment regarding the partnership with with Arzeda:
I believe that the combination of Arzeda’s advanced computational design infrastructure with the TeselaGen platform will yield one of the most advanced information technology systems for the forward engineering of microbial systems in the world.
On January 1, 2018 TeselaGen Biotechnology completed their seed funding round with $2 million in funding from undisclosed investors.
TeselaGen Biotechnology raises a $2,000,000 seed round.
Dow AgroSciences and TeselaGen Expanding Advanced Biodesign Platform for Ag
August 28, 2017
Documentaries, videos and podcasts
- Synthetic biologyInterdisciplinary branch of biology and engineering, applying multiple disciplines to build artificial biological systems for research, engineering, and medical applications.
- Cluster: Synthetic biologyA cluster of topics related to synthetic biology.
- CompanyA company, abbreviated 'co.', is a legal entity made up of an association of people, be they natural, legal, or a mixture of both, for carrying on a commercial or industrial enterprise.